title: Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.
abstract: BACKGROUND
  Many persons who attempt to quit smoking have made previous unsuccessful attempts to quit with pharmacologic aids. An understanding of the impact of these previous attempts to quit is vital for selecting medications that may be more successful in a future attempt to quit. In particular, the effect of repeated use of bupropion SR (Zyban; INN, amfebutamone) on abstinence rates has not been studied previously.
  
  
  METHODS
  This was a multicenter, randomized, double-blind, placebo-controlled study in 450 smokers who had previously used bupropion in a smoking cessation attempt. The study consisted of a screening phase, a 12-week treatment phase, and a follow-up at month 6. Participants made regular clinic visits throughout the treatment phase during which they received brief counseling sessions to encourage abstinence from smoking. The primary end point was continuous abstinence from smoking from weeks 4 through 7. Secondary efficacy end points were examined throughout the treatment phase and at follow-up after 6 months.
  
  
  RESULTS
  In participants receiving bupropion SR, 27% (61 of 226) remained abstinent throughout the period from weeks 4 through 7 compared with 5% (11 of 224) of participants receiving placebo (P <.001). Significantly (P <.001) more participants who received bupropion SR during the treatment phase remained continuously abstinent from the start of week 4 through month 6 (27 of 226; 12%) compared with participants who received placebo (5 of 224; 2%). Eleven participants receiving placebo (5%) and 19 participants receiving bupropion SR (8%) stopped taking the study medication because of an adverse event.
  
  
  CONCLUSIONS
  Bupropion SR is an effective medication for retreatment of smokers who have used bupropion SR previously.
authors.affiliation: Oregon Health Sciences University, Portland, 97201, USA. gonzales@ohsu.edu
authors.forename: D H
authors.initials: DH
authors.lastname: Gonzales
authors.forename: M A
authors.initials: MA
authors.lastname: Nides
authors.forename: L H
authors.initials: LH
authors.lastname: Ferry
authors.forename: R P
authors.initials: RP
authors.lastname: Kustra
authors.forename: B D
authors.initials: BD
authors.lastname: Jamerson
authors.forename: N
authors.initials: N
authors.lastname: Segall
authors.forename: L A
authors.initials: LA
authors.lastname: Herrero
authors.forename: A
authors.initials: A
authors.lastname: Krishen
authors.forename: A
authors.initials: A
authors.lastname: Sweeney
authors.forename: K
authors.initials: K
authors.lastname: Buaron
authors.forename: A
authors.initials: A
authors.lastname: Metz
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D016642:Bupropion / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D016540:Smoking Cessation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D018687:Antidepressive Agents, Second-Generation; D016642:Bupropion